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The Five Pillars of Cancer Treatment
肿瘤免疫疗法
Modified T Cell Therapy For Cancer (CAR-T)
From Rockland Immunochemicals, Inc. 
FDA-Approved CAR-T Products
Current approved indications for PD-1, PD-
L1 and CTLA-4 antibodies by FDA & CFDA 

Sale Figure of PD-1 and PD-L1 antibodies ($ million)
• PD-1 antagonists show wide spectrum of anti-tumor activity in patients
➢Good response in: Hodgkin’s lymphoma (69-87%), melanoma (40－
50%), Merkel-cell carcinoma (33%), gastric (30%), head and neck (20-
30%), RCC (25%), NSCLC (19%), liver (19%), bladder (15%), 
urothelial cancer (20-30%), triple negative breast cancer (20%), 
ovarian cancer (10-23%). 
➢Rare responses in: colon (except the MMR type), prostate cancer, 
pancreatic cancer and multiple myeloma.
• Good safety profile
• Durable responses
PD-1/PD-L1 antibody-based immunotherapy
Challenge  in cancer Immuno-therapy
• Why are many cancer patients still unresponsive to PD-1/PD-L1 
blockade?
• Can we come up with immunotherapy approaches that would 
benefit most of the cancer patients and eventually cure the 
disease?
Non-Inflamed
Excluded Infiltrate
Inflamed
Four Categories of Tumors Based on Presence of PD-L1 and TIL in melanoma (n=256)，
NSCLC (n=457)，bladder cancer（n=126）and colon cancer
Adapted from Sznol and Chen 2013; Velcheti et al. Lab. Invest. 214.
Treatment Options for the four categories of cancer
⚫ Type I and IV: Cold tumors
➢ Anti-CTLA-4
➢ CD40 agonist
➢ Cancer vaccines
➢ Radiation
➢ Chemotherapy
➢ Oncolytic virus
➢ Adoptive cell therapy
⚫ Type III: Other inhibitors?
➢ TIM-3
➢ LAG-3
➢ TIGIT
➢ VISTA
⚫ Type II: hot tumors
➢ PD-1-based therapy
Tumor primary resistance mechanism to immuno-
surveillance
⚫Avoid recognition
⚫Block infiltration
⚫ Inhibit activation
Tumor primary resistance mechanism to immuno-
surveillance
⚫Avoid recognition
• Loss of Ag or MHC expression by tumor cells 
✓ e.g. NLRC5/CITA (Yoshihama et al 2015)
Tumor primary resistance mechanism to immuno-
surveillance
⚫Block infiltration
• Blockade of infiltrating immune cells
✓ b-catenin pathway mediating exclusion of 
T cells from the TME (Spranger et al 2015)
✓Chemokine-mediated exclusion (Li. J. et al 2018)
The Chemokine Yin-Yang regulating T-cell-inflamed and 
non-T-cell-inflamed tumors
Li J. et al. Immunity (2018)
Tumor primary resistance mechanism to immuno-surveillance
⚫ Inhibit activation
• Induction of CTLA-4 in T cells
• Induction of PD-L1 (cancers and APCs) 
and PD-1 (T cells)
➢EGFR mutation can promote PD-L1 
expression in lung cancer 
➢Cell-intrinsic upregulation of PD-L1 
through oncogenic RAS signaling
➢Adaptive response through IFN-g
Krueger J and Rudd CE. Immunity (2017)
Mechanisms of acquired resistance to anti-PD-1 therapy
• Acquired resistance is defined as the recurrence of 
tumors following clear signs of clinical responses 
(partial or complete response).
• Melanoma (Zaretsky et al NEJM 2016； Shin et al Cancer 
Discovery 2017):
➢ JAK1 nonsense mutation
➢ JAK2 slice-site mutation with in-frame stop codon
➢ JAK1/2 inactivating mutations
➢ b2 microglobulin (B2M) 4 bp frame-shift deletion
➢ IFN/b2M loss-of-function mutation
• Colon cancer (MMR deficient) (Shin et al Cancer Discovery 
2017 ):
➢ JAK1/JAK2 inactivating mutations
• Lung cancer (Drs. Politi and Herbst,  reported at 2017 ASCO-
SITC symposium)
➢ b2M loss-of-function mutation
Tumor primary resistance mechanism to immuno-
surveillance
⚫ Inhibit activation
• Induction of CTLA-4 in T cells
• Induction of PD-L1 (cancers and APCs) and PD-1 (T cells)
➢EGFR mutation can promote PD-L1 expression in lung cancer 
➢Cell-intrinsic upregulation of PD-L1 through oncogenic RAS signaling
➢Adaptive response through IFN-g
• Induction of NK-inhibitory proteins
Tumor primary resistance mechanism to immuno-
surveillance
⚫ Inhibit activation
• Induction of CTLA-4 in T cells
• Induction of PD-L1 and PD-1 (T 
cells)
➢ EGFR mutation can promote 
PD-L1 expression in lung 
cancer 
➢ Cell-intrinsic upregulation of 
PD-L1 through oncogenic 
RAS signaling
➢ Adaptive response through 
IFN-g
• Induction of NK-inhibitory 
proteins (e.g.  NKG2A)
Tumor primary resistance mechanism to immuno-
surveillance
⚫ Inhibit activation
• Induction of CTLA-4 in T cells
• Induction of PD-L1 and PD-1 (T cells)
➢EGFR mutation can promote PD-L1 expression in lung cancer (Akbay et al 2013) 
➢Cell-intrinsic upregulation of PD-L1 through oncogenic RAS signaling
➢Adaptive response through IFN-g
• Induction of NK-inhibitory proteins
• Upregulation of “Don’t-eat-me signal” CD47
CD47-SIRPa: Don’t-Eat-Me Signal
Murata Y et al. J Biochem 2014
Expression of CD47 in cancer   
⚫ High CD47 expression was documented in numerous tumors:
➢Blood cancers: AML, ALL, CLL, CML, DLBCL, FL, MCL, MM
➢ Solid cancers: Bladder cancer, Brain cancer, Breast cancer, Colon cancer, Liver cancer, 
Melanoma, Ovarian cancer, Prostate cancer
⚫ Highest level of CD47 was found on cancer stem cells.
⚫ High CD47 expression was associated with disease progression (high CD47 was an adverse 
prognostic factor in human cancers).
CD47 antibody Humab-5F9 and Rituximab in Non-Hodgkin’s Lymphoma
⚫ All of the patients had failed at least 2 
lines of therapy – with a median of 4 
failure (2-10) – before they were 
recruited for the trials; 95% of the 
patients had disease that was 
refractory to rituximab
⚫ 8 patients achieved CR with no sign of 
residual disease
⚫ 3 patients did not respond and died
⚫ Adverse events were predominant of 
grade 1 or 2.
⚫ Anemia was mitigated by 5F9 prime 
and maintenance dosing.
Advani R. et al. NEJM (2018)
Tumor primary resistance mechanism to immuno-
surveillance
⚫ Inhibit activation
• Induction of CTLA-4 in T cells
• Induction of PD-L1 and PD-1 (T cells)
➢ EGFR mutation can promote PD-L1 expression in lung cancer (Akbay et al 2013) 
➢ Cell-intrinsic upregulation of PD-L1 through oncogenic RAS signaling
➢ Adaptive response through IFN-g
• Induction of NK-inhibitory proteins
• Upregulation of “Don’t-eat-me signal” CD47
• Suppressive TME blocking immune activation
➢ Acidic environment
➢ MDSC
➢ TAM
➢ Tregs
➢ Adenosine 
MDSC and Tumor-associated macrophages (TAM) in the tumor 
microenvironment (TME)
Parker, Adv Cancer Res. 2015 ; 128: 95–139. 
Where are the opportunities
• Targeting suppressive TME
➢ TAM, MDSC and Tregs
➢ Adenosine
• Targeting recruitment of immune cells into TME
➢ 48% of non-inflammed melanoma has the upregulation of b-catenin pathway
➢ CXCL1
• Targeting new checkpoint molecules
➢ In T cells
➢ In macrophages
➢ In NK cells
• Study best combinational strategy 
➢ CTLA-4 and PD-1 combo 
➢ It is still early days for combinational therapy. 
Presented By Scott Antonia at 2016 ASCO Annual Meeting
Nivolumab +/- lpilimumab in Recurrent SCLC
Immuno-oncology Combinational Therapy
Immuno-oncology Combinational Therapy
Immune Checkpoint Targets for T cell Regulation
Source: Baumeister et al. Annu. Rev. Immunol.  34:20.1–20.35 (2016)
Immune-Oncology 2.0: Combination
Dual Checkpoint Inhibitors 
Checkpoint Inhibitors + Costimulatory 
Receptor Agonists 
Checkpoint Inhibitors + Immunomodulators      
(Innate Immune Cells) 
Checkpoint inhibitors + Other Immune System 
Activators 
PD-1/PD-L1, CTLA4, LAG-3, TIM-3, VISTA
CD47,  TLR agonists
4-1BB, OX40, CD40
Chemo, IL-2, Vaccines
